SAHaRA: A Randomized Controlled Trial

  • STATUS
    Recruiting
  • End date
    Sep 26, 2024
  • participants needed
    740
  • sponsor
    Ottawa Hospital Research Institute
Updated on 2 March 2022

Summary

The SAHaRA trial will clarify the role of treating anemia with Red Blood Cell (RBC) transfusion in a unique and vulnerable patient population, and determine whether that impacts on functional outcomes and mortality. It will guide best practice standards and clarify the optimal RBC transfusion strategy in patients with aSAH.

Description

We hypothesize that in adult patients suffering from aSAH and anemia, a liberal RBC transfusion strategy as compared to a restrictive RBC transfusion strategy decreases the combined rate of death and severe disability at 12 months (using the modified Rankin Scale)

Details
Condition Subarachnoid Hemorrhage, Aneurysmal
Treatment Liberal RBC Transfusion Strategy, Restrictive RBC Transfusion Strategy
Clinical Study IdentifierNCT03309579
SponsorOttawa Hospital Research Institute
Last Modified on2 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years old at time of SAH
First ever episode of aneurysmal SAH
Diagnosis of aSAH as confirmed by treating physician (eg: neurosurgeon or neurointerventionalist) and supported by blood in subarachnoid space (e.g. cranial imaging or cerebrospinal fluid positive for xanthochromia, surgical visualization) that is the result of a ruptured aneurysm (e.g. direct visualization, cranial imaging or catheter angiogram)
Hb 100g/L within 10 days following aSAH (defined by first day of hospital presentation)

Exclusion Criteria

Physician and or family decision to withdraw/withhold active medical care at time of enrolment
Active bleeding with hemodynamic instability at time of enrolment
Patients with contraindication or known objection to blood transfusions
SAH due to mycotic aneurysm, infundibulum and vascular malformations
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note